Patents by Inventor Robert Maclaren

Robert Maclaren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF STARGARDT DISEASE
    Publication number: 20210147870
    Abstract: The present disclosure provides an adeno-associated viral (AAV) vector system for expressing a human ABCA4 protein in a target cell, the AAV vector system comprising a first AAV vector comprising a first nucleic acid sequence and a second AAV vector comprising a second nucleic acid sequence; wherein the first nucleic acid sequence comprises a 5? end portion of an ABCA4 coding sequence (CDS) and the second nucleic acid sequence comprises a 3? end portion of an ABCA4 CDS, and the 5? end portion and the 3? end portion together encompass the entire ABCA4 CDS; wherein the first nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 105 to 3597 of SEQ ID NO: 1; wherein the second nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 3806 to 6926 of SEQ ID NO: 1; wherein the first nucleic acid sequence and the second nucleic acid sequence each comprise a region of sequence overlap with the other; and wherein the region of sequence
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Inventors: Gregory S. Robinson, Michelle E. McClements, Robert Maclaren
  • TREATMENT OF RETINITIS PIGMENTOSA
    Publication number: 20210130425
    Abstract: A polynucleotide comprising a nucleotide sequence encoding the retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15), wherein the RPGRORF15-encoding nucleotide sequence has been codon optimised to increase fidelity of replication of the sequence.
    Type: Application
    Filed: October 7, 2020
    Publication date: May 6, 2021
    Inventors: Robert Maclaren, Dominik Fischer
  • AAV-VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIA
    Publication number: 20210032656
    Abstract: The present invention relates to gene therapy for treatment or prevention of choroideremia.
    Type: Application
    Filed: January 24, 2020
    Publication date: February 4, 2021
    Inventors: Robert Maclaren, Miguel Seabra, Matthew John During
  • Treatment of retinitis pigmentosa
    Patent number: 10836803
    Abstract: A polynucleotide comprising a nucleotide sequence encoding the retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15), wherein the RPGRORF15-encoding nucleotide sequence has been codon optimised to increase fidelity of replication of the sequence.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: November 17, 2020
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Robert MacLaren, Dominik Fischer
  • PRENYLATION ASSAY
    Publication number: 20200341015
    Abstract: A method for determining the activity of Rab escort protein 1 (REP1) comprising the steps: (a) providing a sample comprising REP1; (b) contacting the sample of step (a) with Rab6a, Rab geranylgeranyltransferase (Rab GGTase) and a lipid donor substrate; and (c) detecting the lipidated Rab6a product.
    Type: Application
    Filed: October 17, 2018
    Publication date: October 29, 2020
    Inventors: Robert Maclaren, Maria Ines Moreira Patricio, Gregory S. Robinson
  • TREATMENT OF EYE DISEASE
    Publication number: 20200306341
    Abstract: A method of treating an eye disease comprising administering an adeno-associated virus (AAV) vector to a mammalian subject by subretinal injection, wherein the AAV vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.
    Type: Application
    Filed: January 9, 2020
    Publication date: October 1, 2020
    Inventors: Robert Maclaren, Alun R. Barnard, Samantha R. De Silva, Mark W. Hankins
  • TREATMENT OF RETINITIS PIGMENTOSA
    Publication number: 20200002392
    Abstract: A polynucleotide comprising a nucleotide sequence encoding the retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15), wherein the RPGRORF15-encoding nucleotide sequence has been codon optimised to increase fidelity of replication of the sequence.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 2, 2020
    Inventors: Robert MacLaren, Dominik Fischer
  • COMPOSITIONS AND METHODS FOR TREATING MACULAR DYSTROPHY
    Publication number: 20190307900
    Abstract: The disclosure provides composition comprising a nucleic acid sequence comprising (a) a sequence encoding a vitelliform macular dystrophy-2 (VMD2) promoter, and (b) a sequence encoding a Bestrophin-1 (BEST1) protein as well as the use of these compositions for the treatment of macular dystrophy in a subject comprising administration of the composition to an eye of a subject via a subretinal or a suprachoroidal route.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 10, 2019
    Inventors: Robert MACLAREN, Christina MARTINEZ-FERNANDEZ DE LA CAMAR, Gregory S. ROBINSON
  • DUAL OVERLAPPING ADENO-ASSOCIATED VIRAL VECTOR SYSTEM FOR EXPRESSING ABCA4
    Publication number: 20190309326
    Abstract: The present invention provides an adeno-associated viral (AAV) vector system for expressing a human ABCA4 protein in a target cell, the AAV vector system comprising a first AAV vector comprising a first nucleic acid sequence and a second AAV vector comprising a second nucleic acid sequence; wherein the first nucleic acid sequence comprises a 5? end portion of an ABCA4 coding sequence (CDS) and the second nucleic acid sequence comprises a 3? end portion of an ABCA4 CDS, and the 5? end portion and the 3? end portion together encompass the entire ABCA4 CDS; wherein the first nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 105 to 3597 of SEQ ID NO: 1; wherein the second nucleic acid sequence comprises a sequence of contiguous nucleotides corresponding to nucleotides 3806 to 6926 of SEQ ID NO: 1; wherein the first nucleic acid sequence and the second nucleic acid sequence each comprise a region of sequence overlap with the other; and wherein the region of sequence
    Type: Application
    Filed: June 14, 2017
    Publication date: October 10, 2019
    Inventors: Robert MACLAREN, Michelle MCCLEMENTS
  • TREATMENT OF EYE DISEASE
    Publication number: 20190282658
    Abstract: A method of treating an eye disease comprising administering an adeno-associated virus (AAV) vector to a mammalian subject by subretinal injection, wherein the AAV vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.
    Type: Application
    Filed: April 12, 2019
    Publication date: September 19, 2019
    Inventors: Robert MACLAREN, Alun R. BARNARD, Samantha R. DE SILVA, Mark W. HANKINS
  • TREATMENT OF EYE DISEASE
    Publication number: 20180360912
    Abstract: A method of treating an eye disease comprising administering an adeno-associated virus (AAV) vector to a mammalian subject by subretinal injection, wherein the AAV vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.
    Type: Application
    Filed: August 31, 2018
    Publication date: December 20, 2018
    Inventors: Robert MACLAREN, Alun R. BARNARD, Samantha R. DE SILVA, Mark W. HANKINS
  • TREATMENT OF RETINITIS PIGMENTOSA
    Publication number: 20180273594
    Abstract: A polynucleotide comprising a nucleotide sequence encoding the retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15), wherein the RPGRORF15-encoding nucleotide sequence has been codon optimised to increase fidelity of replication of the sequence.
    Type: Application
    Filed: September 9, 2016
    Publication date: September 27, 2018
    Inventors: Robert MACLAREN, Dominik FISCHER
  • AAV-VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIA
    Publication number: 20180135078
    Abstract: The present invention relates to gene therapy for treatment or prevention of choroideremia.
    Type: Application
    Filed: October 31, 2017
    Publication date: May 17, 2018
    Inventors: Robert MACLAREN, Miguel SEABRA, Matthew John DURING
  • TREATMENT OF EYE DISEASE
    Publication number: 20180042992
    Abstract: A method of treating an eye disease comprising administering an adeno-associated virus (AAV) vector to a mammalian subject by subretinal injection, wherein the AAV vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.
    Type: Application
    Filed: October 30, 2017
    Publication date: February 15, 2018
    Inventors: Robert MACLAREN, Alun R. BARNARD, Samantha R. DE SILVA, Mark W. HANKINS
  • AAV -vectors for use in gene therapy of choroideremia
    Patent number: 9834788
    Abstract: The present invention relates to gene therapy for treatment or prevention of choroideremia.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: December 5, 2017
    Assignee: Oxford University Innovation Limited
    Inventors: Robert Maclaren, Miguel Seabra, Matthew John During
  • METHOD
    Publication number: 20160206704
    Abstract: A method of using a vector comprising a transgene to treat a disease or condition of the eye, the method comprising the steps: (a) administering a solution to a mammalian subject by subretinal injection in an amount effective to at least partially detach the retina to form a subretinal bleb, wherein the solution does not comprise the vector; and (b) administering a medicament composition by subretinal injection into the bleb formed by step (a), wherein the medicament comprises the vector and is injected in an amount effective to treat the disease or condition; wherein the transgene is expressible in cells of the mammalian subject.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 21, 2016
    Inventor: Robert MacLaren
  • AAV -VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIA
    Publication number: 20140107185
    Abstract: The present invention relates to gene therapy for treatment or prevention of choroideremia.
    Type: Application
    Filed: February 21, 2012
    Publication date: April 17, 2014
    Applicant: ISIS INNOVATION LIMITED
    Inventors: Robert Maclaren, Miguel Seabra, Matthew John During